62 results
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
12 Apr 24
Regulation FD Disclosure
6:37pm
Exhibit 99.1
INVESTOR PRESENTATION April 2024 www.CNSPharma.com NASDAQ: CNSP
NASDAQ: CNSP This presentation incorporates information from materials
8-K
CNSP
Cns Pharmaceuticals Inc
21 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
continuing operations set forth in the Listing Rule. Based on the Staff’s review and the materials provided to the Staff by the Company, the Staff granted
8-K
EX-1.1
2yu720u3e 4tb
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
2jxdltn8mtbaq9bys
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
424B4
o0dvedk 0xaew
31 Jan 24
Prospectus supplement with pricing info
4:27pm
8-K
EX-10.1
ynopv 7q0g
17 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.2
ru1bsp4 vs
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm
8-K
EX-10.1
fafgccp283 b8r6
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm